Immpact Bio USA
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $115M
Investors
- 12
About Immpact Bio USA
Immpact Bio USA Inc.Founded in 2017 and headquartered in Camarillo, US, Immpact Bio USA Inc. specializes in creating advanced CAR T cell therapies. The company was formed to leverage cutting-edge technology in addressing difficult medical conditions. Recently, on October 24, 2024, Immpact Bio was acquired by Lyell Immunopharma, Inc.00 mn in cash, strengthening Lyell's cancer treatment pipeline.ImmPACT Bio specializes in the development of innovative bispecific Chimeric Antigen Receptor (CAR) T cell therapies aimed at addressing significant challenges in oncology and autoimmune diseases. Their core products leverage cutting-edge iCAR technology, designed to selectively target and eliminate cancer cells while preserving normal tissue, with applications across all solid tumors. The company’s product offerings include advanced CAR T cell platforms that focus on preventing antigen escape and overcoming the immunosuppressive microenvironment commonly found in cancers. ImmPACT Bio's therapies are primarily aimed at healthcare providers, clinical research institutions, and pharmaceutical partners involved in treating patients with grievous diseases, particularly in areas such as systemic lupus erythematosus (SLE) and various types of cancers.ImmPACT Bio generates revenue through strategic partnerships and collaborations with pharmaceutical companies and research institutions, focused on the commercialization of their advanced CAR T cell therapies. The structure of transactions typically involves joint development agreements and licensing arrangements, allowing partners to leverage ImmPACT Bio's proprietary technologies in exchange for upfront payments and milestone payments as products advance through clinical trials and regulatory approvals. Additionally, revenue may be driven by revenue-sharing models post-commercialization, where partners distribute the therapies to healthcare providers and institutions.00 mn will bolster Lyell's focus on next-generation CAR T-cell therapies, particularly IMPT-314 that addresses cancer treatments. This strategic move will likely expand Immpact Bio's product offerings and market reach, reinforcing their commitment to innovative cancer therapies.
Who invested in Immpact Bio USA
12 investors across 2 rounds
See all investors in Immpact Bio USA
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immpact Bio USA
Who invested in Immpact Bio USA?
Immpact Bio USA has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immpact Bio USA raised?
Immpact Bio USA has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Immpact Bio USA last raise money?
Immpact Bio USA's most recent round on record is a Series B, in Jan 2022.
What does Immpact Bio USA do?
Immpact Bio USA is a biotechnology company.
Where is Immpact Bio USA headquartered?
Immpact Bio USA is headquartered in Camarillo, US.
Which VCs invest in companies like Immpact Bio USA?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immpact Bio USA's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immpact Bio USA? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.